EQRx Inc. made a big splash at the start of 2020 when it launched with $200m in series A venture capital, not to chase novel drug targets or modalities, but to develop small molecules and antibodies against well-known targets. The goal wasn’t to be first to market, but to have the cheapest drug. Now the company has disclosed license agreements for two cancer drugs in blockbuster categories – still without revealing its strategy for bringing less expensive medicines to market.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
